Best Hospitals for Skin Cancer Treatment in Dubai, UAE

Skin cancer arises from the uncontrolled proliferation of cutaneous cells, with three predominant histological subtypes: basal cell carcinoma (BCC), the most common malignancy worldwide; squamous cell carcinoma (SCC), which carries meaningful metastatic risk if neglected; and melanoma, the most aggressive form, originating from melanocytes and capable of rapid lymphatic and hematogenous spread. Additional rarer entities — Merkel cell carcinoma, dermatofibrosarcoma protuberans (DFSP), and cutaneous lymphomas — require subspecialty oncologic expertise. The physiological impact of advanced skin cancer extends well beyond the dermis: melanoma in particular exhibits a propensity to metastasize to regional lymph nodes, liver, lung, brain, and bone, triggering systemic inflammatory cascades and significant morbidity. SCC in immunocompromised patients (post-transplant recipients, HIV-positive individuals) can behave with near-melanoma aggression, necessitating vigilant multidisciplinary review.

• ELIGIBLE PATIENTS:
• Histologically confirmed skin cancer (BCC, SCC, melanoma, Merkel cell carcinoma, DFSP, cutaneous T-cell lymphoma) at any stage, from in situ to Stage IV requiring systemic therapy
• Patients with recurrent or incompletely excised primary tumors seeking definitive re-excision or Mohs surgery
• Melanoma patients requiring sentinel lymph node biopsy (SLNB), completion lymph node dissection (CLND), or isolated limb perfusion (ILP) for regionally advanced disease
• Patients with BRAF V600E/K-mutant melanoma (confirmed by molecular profiling) eligible for targeted therapy (dabrafenib + trametinib; vemurafenib + cobimetinib)
• +21 more

Surgical APPROACHES:

1. Mohs Micrographic Surgery (MMS): The oncologic gold standard for high-risk BCC and SCC in cosmetically or functionally critical anatomic sites (H-zone of the face, ears, nose, eyelids, lips, genitalia, hands, feet). The procedure involves sequential horizontal tissue excision with immediate intraoperative frozen-section margin analysis — processing 100% of the peripheral and deep surgical margins (versus the 1–2% sampled by bread-loafing in standard excision). Each stage is mapped, color-coded, and processed in a cryostat on-site. Cure rates: 99% for primary BCC, 97% for recurrent BCC, 95–97% for primary SCC. Typically performed under local anesthesia as a same-day outpatient procedure.

2. Wide Local Excision (WLE): Standard surgical approach for melanoma, with margins defined by Breslow thickness per NCCN guidelines (in situ: 0.5–1 cm; ≤1 mm: 1 cm; 1.01–2 mm: 1–2 cm; >2 mm: 2 cm). Performed under local or general anesthesia depending on lesion size and location; may require reconstructive closure with primary repair, split-thickness skin grafting (STSG), or local advancement/rotation/transposition flaps.

3. Sentinel Lymph Node Biopsy (SLNB): Indicated for melanoma ≥0.8 mm Breslow thickness (or ≥0.6 mm with adverse features: ulceration, mitotic rate ≥2/mm², lymphovascular invasion). Technetium-99m nanocolloid lymphoscintigraphy maps the sentinel node basin pre-operatively; intraoperative gamma probe + isosulfan blue/Patent Blue dye identifies the sentinel node(s) for excision. Pathological assessment by step-serial sectioning with H&E and S100/HMB-45 IHC. SLNB provides critical prognostic staging and guides adjuvant therapy decisions.

PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (Weeks 1–2 before travel):

• Patient submits existing biopsy reports, dermoscopy images, histopathology slides (digitized), and imaging (PET-CT, MRI, CT) to GAF Healthcare's oncology case management team
• GAF Healthcare facilitates asynchronous tumor board review by destination hospital's dermatologic oncology MDT (multidisciplinary team), with formal treatment recommendation issued within 48–72 hours
• Molecular pathology review: BRAF/NRAS/c-KIT mutation status and PD-L1 expression confirmed; if profiling is incomplete, GAF arranges sample re-testing at destination laboratory
• GAF Healthcare assists with e-Medical Visa application (India) or UAE entry documentation; medical invitation letter issued by treating hospital
• Pre-travel checklist issued: medications to pause (anticoagulants, immunosuppressants, biologics with washout requirements), baseline blood tests to obtain locally, and fitness-to-travel clearance if needed

PHASE 2 — ARRIVAL & BASELINE ASSESSMENT (Days 1–3):